Sumitomo Pharmaceuticals Company Limited

Ltt Bio-pharma Co., Ltd.

Chikao Nakayama

Hiroshi Noguchi

Mutsuo Taiji

Junji Ichihara

Michiko Kishino

Yutaka Mizushima

Toru Kimura

Kaoru Kikuchi

Rie Igarashi

Akira Ito

Yoko Ishige

Makoto Inoue

Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.

Modified BDNF

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Hepatocyte growth factor for treatment of diabetes

Remedies for diabetes

Factors mutated in the D1 cap region

Growing community of inventors

Sanda, Japan

Chikao Nakayama